Glioblastoma (GBM) is a primary neuroepithelial tumor of the central nervous system,
characterized by an extremely aggressive clinical phenotype. Patients with GBM have a …

Glioblastoma is the most frequent and most malignant human brain tumor. The prognosis
remains very poor, with most patients dying within 1 year after diagnosis. Primary and …

Published data on prognostic and predictive factors in patients with gliomas are largely
based on clinical trials and hospital-based studies. This review summarizes data on …

We conducted a population-based study on glioblastomas in the Canton of Zurich,
Switzerland (population, 1.16 million) to determine the frequency of major genetic alterations …

Gliomas are the most common primary brain tumors. They account for more than 70% of all
neoplasms of the central nervous system and vary considerably in morphology, location …

Glioblastoma multiforme, the most malignant human brain tumor, may develop de nova
(primary glioblastoma) or through progression from low‐grade or anaplastic astrocytoma …

Current glioblastoma therapies are insufficient to prevent tumor recurrence and eventual
death. Here, we describe a method to treat malignant glioma by nonviral DNA delivery using …

Glioblastoma multiforme (GBM), a WHO grade IV malignant glioma, is the most common and
lethal primary brain tumor in adults; few treatments are available. Median survival rates …

Glioblastoma multiforme (GBM) is the most common primary brain tumour in adults and one
of the most aggressive cancers in man. Despite technological advances in surgical …

Purpose: Advances in brain tumor biology indicate that transfer of p53 is an alternative
therapy for human gliomas. Consequently, we undertook a phase I clinical trial of p53 gene …